Penn Medicine Provider
Hematology
Pashna N. Munshi, MD
5.0
(66)
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 4th Floor West

About me

  • Associate Professor of Clinical Medicine (Hematology-Oncology)

Education and training

  • Medical School: K.J. Somaiya Medical College
  • Residency: Cooper University Hospital

What my patients think about me

Average Rating
5.0

66 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

July 2025
5.0
5.0
very knowledgeable
July 2025
5.0
5.0
just a solid dr
July 2025
5.0
5.0
Dr Munshi provided details of what to expect.
June 2025
5.0
5.0
great

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Munshi is a Penn Medicine physician.

Qualifications and experience

My research

Farhan S, Kennedy VE, Espinoza-Gutarra MR, Lust H, Bobillo MSO, Lin AY, Olin RL, Lin RJ, Rentscher KE, Taylor MR, Mohanraj L, Wood WA, Murthy HS, Ahmed N, Dueck AC, Phelan R, Kelly DL, Yuen C, Munshi PN, Schoemans H, Hamilton BK, Lee C, Sung AD. Assessing physical function in transplantation and CAR-T recipients: expert recommendations from the survivorship, aging and biobehavioral special interest groups of ASTCT , Transplant Cell Ther: 2025


Shan X, Kuiper R, Ding C, Munshi PN, Stadtmauer EA, Susanibar-Adaniya SP. Age-related disparities in treatment and outcomes for newly diagnosed multiple myeloma: a population-based study , Haematologica: 2025


Munshi PN, Olin RL, Wall S, McCurdy SR, Al-Juhaishi T, Baker J, Bhatt VR, Chokr N, Dahi P, DeFilipp Z, Espinoza-Gutarra M, Farhan S, Gowda L, Hamilton BK, Inamoto Y, Jayani R, Kharfan-Dabaja MA, Lin R, Meyers G, Mishra A, Murthy HS, Nawas M, Rosko AE, Ruiz M, Sorror ML, Sung AD, Carpenter PA, Hamadani M, Artz AS. US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or Chimeric Antigen Receptor T Cell Therapy: An American Society for Transplantation and Cellular Therapy Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines , Transplant Cell Ther: 2025


Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson M, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Rosenblatt J, Korn R, Peng W, Lui C, Wulff J, Shen R, Poddar S, Jung AS, Miao H, Beygi S, Jacobson CA. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5) , Blood, 143: 2024,496-506


Hashmi H, Kumar A, Kharfan-Dabaja MA, Munshi PN, Inamoto Y, DeFilipp Z, Dholaria B, Jain T, Perales MA, Carpenter PA, Hamadani M, Dhakal B, Usmani SZ. ASTCT Committee on Practice Guidelines Survey on Evaluation and Management of Relapsed/Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T Cell Therapy , Transplant Cell Ther: 2024


Ustun C, Chen M, Kim S, Auletta JJ, Batista MV, Battiwalla M, Cerny J, Gowda L, Hill JA, Liu H, Munshi PN, Nathan S, Seftel MD, Wingard JR, Chemaly RF, Dandoy CE, Perales MA, Riches M, Papanicolaou GA. Post-transplantation cyclophosphamide is associated with increased bacterial infections , Bone Marrow Transplant: 2024


Munshi PN, McCurdy SR. Age barriers in allogeneic hematopoietic cell transplantation: Raising the silver curtain , Am J Hematol: 2024


Murthy HS, Zhang MJ, Chen K, Ahmed S, Deotare U, Ganguly S, Kansagra A, Michelis FV, Nishihori T, Patnaik M, Abid MB, Aljurf M, Arai Y, Bacher U, Badar T, Badawy SM, Ballen K, Battiwalla M, Beitinjaneh A, Bejanyan N, Bhatt VR, Brown VI, Martino R, Cahn JY, Castillo P, Cerny J, Chhabra S, Copelan E, Daly A, Dholaria B, Diaz Perez MA, Freytes CO, Grunwald MR, Hashmi S, Hildebrandt GC, Jamy O, Joseph J, Kanakry CG, Khera N, Krem MM, Kuwatsuka Y, Lazarus HM, Lekakis LJ, Liu H, Modi D, Munshi PN, Mussetti A, Palmisiano N, Patel SS, Rizzieri DA, Seo S, Shah MV, Sharma A, Sohl M, Solomon SR, Ulrickson M, Ustun C, van der Poel M, Verdonck LF, Wagner JL, Wang T, Wirk B, Zeidan A, Litzow M, Kebriaei P, Hourigan CS, Weisdorf DJ, Saber W, Kharfan-Dabaja MA. Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis , Blood Adv, 7: 2023,7007-7016


Munshi PN, Mehta R, McCurdy S. The Effect of Graft-Versus-Host Disease Prophylaxis on Survival after HLA-Matched Hematopoietic cell transplantation (HCT): a CIBMTR analysis. , Transcatheter Cardiovascular Therapeutics Conference, San Fransisco, CA.: 2023


Ragon BK, Shah MV, D'Souza A, Estrada-Merly N, Gowda L, George G, de Lima M, Hashmi S, Kharfan-Dabaja MA, Majhail NS, Banerjee R, Saad A, Hildebrandt GC, Mian H, Abid MB, Battiwalla M, Lekakis LJ, Patel SS, Murthy HS, Nieto Y, Strouse C, Badawy SM, Al Hadidi S, Dholaria B, Aljurf M, Vesole DH, Lee CH, Pawarode A, Gergis U, Miller KC, Holmberg LA, Afrough A, Solh M, Munshi PN, Nishihori T, Anderson LD Jr, Wirk B, Kaur G, Qazilbash MH, Shah N, Kumar SK, Usmani SZ. Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis , Blood Adv, 7: 2023,2746-2757